Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | RRM1 | P23921 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337609 | 0.82 | USP2 (0.50) | DPP4DPP7RRM1USP2TSHR | |
| SCHEMBL1337607 | 0.82 | USP2 (0.50) | DPP4DPP7RRM1USP2TSHR | |
| SCHEMBL4115911 | 0.81 | DPP4 (0.40) | DPP4DPP7RRM1USP2TSHR | |
| Hydrochloric Acid SCHEMBL1219003 | 0.80 | USP2 (0.48) | DPP4DPP7RRM1USP2TSHR | |
| Hydrochloric Acid SCHEMBL1219006 | 0.80 | USP2 (0.48) | DPP4DPP7RRM1USP2TSHR | |
| SCHEMBL5873375 | 0.80 | DPP4 (0.42) | DPP4DPP7RRM1USP2TSHR | |
| SCHEMBL13688874 | 0.80 | DPP4 (0.42) | DPP4DPP7RRM1USP2TSHR | |
| SCHEMBL12884760 | 0.80 | DPP4 (0.42) | DPP4DPP7RRM1USP2TSHR | |
| SCHEMBL13688877 | 0.80 | DPP4 (0.42) | DPP4DPP7RRM1USP2TSHR | |
| SCHEMBL5873393 | 0.80 | DPP4 (0.42) | DPP4DPP7RRM1USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | DPP4 4359/4885DPP7 3990/4885RRM1 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.